North Central Cancer Treatment group N10C2 (Alliance): A double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes

Haeseong Park, Rui Qin, Thomas J. Smith, Pamela J. Atherton, Debra L. Barton, Keren Sturtz, Shaker R. Dakhil, Daniel M. Anderson, Kathleen Flynn, Suneetha Puttabasavaiah, Nguyet Anh Le-Lindqwister, Gilbert D A Padula, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Hot flashes are a common symptom in breast cancer survivors that can negatively impact quality of life. Preliminary data suggested that magnesium might be used as an effective low-cost treatment of hot flashes with minimal adverse effects. Methods A four-arm, double-blind, placebo-controlled, randomized trial was conducted. Postmenopausal women with a history of breast cancer and bothersome hot flashes were randomized into treatment groups of magnesium oxide 800 or 1,200 mg daily or corresponding placebo groups at a 2:2:(1:1) ratio. Hot flash frequency and hot flash score (number × mean severity) were measured using a validated hot flash diary. A 1-week baseline period preceded initiation of study medication. The primary endpoint was intrapatient difference in mean hot flash score between baseline and treatment periods, comparing each magnesium group with the combined placebo groups using a gatekeeping procedure. Results were analyzed using repeated-measures and growth curve models on weekly hot flash scores based on a modified intent-to-treat principle. Results Two hundred eighty-nine women enrolled between December 2011 and March 2013. Study groups were well balanced for baseline characteristics. Mean hot flash scores, mean hot flash frequencies, and associated changes during the treatment period were similar for each group. An increased incidence of diarrhea and a corresponding lower incidence of constipation were reported in magnesium arms compared with placebo. No statistically significant difference in other toxicities or quality-of-life measures was observed. Conclusions The results of this trial do not support the use of magnesium oxide for hot flashes.

Original languageEnglish (US)
Pages (from-to)627-632
Number of pages6
JournalMenopause
Volume22
Issue number6
DOIs
StatePublished - Jun 6 2015

Fingerprint

Hot Flashes
Magnesium
Placebos
Neoplasms
Magnesium Oxide
Therapeutics
Gatekeeping
Quality of Life
Breast Neoplasms
Incidence
Constipation
Health Care Costs
Survivors
Diarrhea
Randomized Controlled Trials

Keywords

  • Breast cancer survivorship
  • Hot flashes
  • Magnesium

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

North Central Cancer Treatment group N10C2 (Alliance) : A double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. / Park, Haeseong; Qin, Rui; Smith, Thomas J.; Atherton, Pamela J.; Barton, Debra L.; Sturtz, Keren; Dakhil, Shaker R.; Anderson, Daniel M.; Flynn, Kathleen; Puttabasavaiah, Suneetha; Le-Lindqwister, Nguyet Anh; Padula, Gilbert D A; Loprinzi, Charles Lawrence.

In: Menopause, Vol. 22, No. 6, 06.06.2015, p. 627-632.

Research output: Contribution to journalArticle

Park, H, Qin, R, Smith, TJ, Atherton, PJ, Barton, DL, Sturtz, K, Dakhil, SR, Anderson, DM, Flynn, K, Puttabasavaiah, S, Le-Lindqwister, NA, Padula, GDA & Loprinzi, CL 2015, 'North Central Cancer Treatment group N10C2 (Alliance): A double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes', Menopause, vol. 22, no. 6, pp. 627-632. https://doi.org/10.1097/GME.0000000000000374
Park, Haeseong ; Qin, Rui ; Smith, Thomas J. ; Atherton, Pamela J. ; Barton, Debra L. ; Sturtz, Keren ; Dakhil, Shaker R. ; Anderson, Daniel M. ; Flynn, Kathleen ; Puttabasavaiah, Suneetha ; Le-Lindqwister, Nguyet Anh ; Padula, Gilbert D A ; Loprinzi, Charles Lawrence. / North Central Cancer Treatment group N10C2 (Alliance) : A double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. In: Menopause. 2015 ; Vol. 22, No. 6. pp. 627-632.
@article{68cc6f8aa0be4e2f9597d0b0ca925e48,
title = "North Central Cancer Treatment group N10C2 (Alliance): A double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes",
abstract = "Hot flashes are a common symptom in breast cancer survivors that can negatively impact quality of life. Preliminary data suggested that magnesium might be used as an effective low-cost treatment of hot flashes with minimal adverse effects. Methods A four-arm, double-blind, placebo-controlled, randomized trial was conducted. Postmenopausal women with a history of breast cancer and bothersome hot flashes were randomized into treatment groups of magnesium oxide 800 or 1,200 mg daily or corresponding placebo groups at a 2:2:(1:1) ratio. Hot flash frequency and hot flash score (number × mean severity) were measured using a validated hot flash diary. A 1-week baseline period preceded initiation of study medication. The primary endpoint was intrapatient difference in mean hot flash score between baseline and treatment periods, comparing each magnesium group with the combined placebo groups using a gatekeeping procedure. Results were analyzed using repeated-measures and growth curve models on weekly hot flash scores based on a modified intent-to-treat principle. Results Two hundred eighty-nine women enrolled between December 2011 and March 2013. Study groups were well balanced for baseline characteristics. Mean hot flash scores, mean hot flash frequencies, and associated changes during the treatment period were similar for each group. An increased incidence of diarrhea and a corresponding lower incidence of constipation were reported in magnesium arms compared with placebo. No statistically significant difference in other toxicities or quality-of-life measures was observed. Conclusions The results of this trial do not support the use of magnesium oxide for hot flashes.",
keywords = "Breast cancer survivorship, Hot flashes, Magnesium",
author = "Haeseong Park and Rui Qin and Smith, {Thomas J.} and Atherton, {Pamela J.} and Barton, {Debra L.} and Keren Sturtz and Dakhil, {Shaker R.} and Anderson, {Daniel M.} and Kathleen Flynn and Suneetha Puttabasavaiah and Le-Lindqwister, {Nguyet Anh} and Padula, {Gilbert D A} and Loprinzi, {Charles Lawrence}",
year = "2015",
month = "6",
day = "6",
doi = "10.1097/GME.0000000000000374",
language = "English (US)",
volume = "22",
pages = "627--632",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - North Central Cancer Treatment group N10C2 (Alliance)

T2 - A double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes

AU - Park, Haeseong

AU - Qin, Rui

AU - Smith, Thomas J.

AU - Atherton, Pamela J.

AU - Barton, Debra L.

AU - Sturtz, Keren

AU - Dakhil, Shaker R.

AU - Anderson, Daniel M.

AU - Flynn, Kathleen

AU - Puttabasavaiah, Suneetha

AU - Le-Lindqwister, Nguyet Anh

AU - Padula, Gilbert D A

AU - Loprinzi, Charles Lawrence

PY - 2015/6/6

Y1 - 2015/6/6

N2 - Hot flashes are a common symptom in breast cancer survivors that can negatively impact quality of life. Preliminary data suggested that magnesium might be used as an effective low-cost treatment of hot flashes with minimal adverse effects. Methods A four-arm, double-blind, placebo-controlled, randomized trial was conducted. Postmenopausal women with a history of breast cancer and bothersome hot flashes were randomized into treatment groups of magnesium oxide 800 or 1,200 mg daily or corresponding placebo groups at a 2:2:(1:1) ratio. Hot flash frequency and hot flash score (number × mean severity) were measured using a validated hot flash diary. A 1-week baseline period preceded initiation of study medication. The primary endpoint was intrapatient difference in mean hot flash score between baseline and treatment periods, comparing each magnesium group with the combined placebo groups using a gatekeeping procedure. Results were analyzed using repeated-measures and growth curve models on weekly hot flash scores based on a modified intent-to-treat principle. Results Two hundred eighty-nine women enrolled between December 2011 and March 2013. Study groups were well balanced for baseline characteristics. Mean hot flash scores, mean hot flash frequencies, and associated changes during the treatment period were similar for each group. An increased incidence of diarrhea and a corresponding lower incidence of constipation were reported in magnesium arms compared with placebo. No statistically significant difference in other toxicities or quality-of-life measures was observed. Conclusions The results of this trial do not support the use of magnesium oxide for hot flashes.

AB - Hot flashes are a common symptom in breast cancer survivors that can negatively impact quality of life. Preliminary data suggested that magnesium might be used as an effective low-cost treatment of hot flashes with minimal adverse effects. Methods A four-arm, double-blind, placebo-controlled, randomized trial was conducted. Postmenopausal women with a history of breast cancer and bothersome hot flashes were randomized into treatment groups of magnesium oxide 800 or 1,200 mg daily or corresponding placebo groups at a 2:2:(1:1) ratio. Hot flash frequency and hot flash score (number × mean severity) were measured using a validated hot flash diary. A 1-week baseline period preceded initiation of study medication. The primary endpoint was intrapatient difference in mean hot flash score between baseline and treatment periods, comparing each magnesium group with the combined placebo groups using a gatekeeping procedure. Results were analyzed using repeated-measures and growth curve models on weekly hot flash scores based on a modified intent-to-treat principle. Results Two hundred eighty-nine women enrolled between December 2011 and March 2013. Study groups were well balanced for baseline characteristics. Mean hot flash scores, mean hot flash frequencies, and associated changes during the treatment period were similar for each group. An increased incidence of diarrhea and a corresponding lower incidence of constipation were reported in magnesium arms compared with placebo. No statistically significant difference in other toxicities or quality-of-life measures was observed. Conclusions The results of this trial do not support the use of magnesium oxide for hot flashes.

KW - Breast cancer survivorship

KW - Hot flashes

KW - Magnesium

UR - http://www.scopus.com/inward/record.url?scp=84930485391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930485391&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000000374

DO - 10.1097/GME.0000000000000374

M3 - Article

C2 - 25423327

AN - SCOPUS:84930485391

VL - 22

SP - 627

EP - 632

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 6

ER -